Skip to main content

Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD

Oncology Data Advisor® · Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD Last year, Brian Rubin, MD, PhD, Chair of Pathology and Laboratory Medicine and the Chief of Diagnostics at the Cleveland Clinic, served as co-chair for i3 Health's continuing medical education (CME)–/nursing continuing professional development (NCPD)–approved virtual tumor board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma, alongside Kathleen Polson, Nurse Practitioner at Da...

Continue reading

Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD

Last year, Brian Rubin, MD, PhD, Chair of Pathology and Laboratory Medicine and the Chief of Diagnostics at the Cleveland Clinic, served as co-chair for i3 Health's continuing medical education (CME)–/nursing continuing professional development (NCPD)–approved virtual tumor board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma, alongside Kathleen Polson, Nurse Practitioner at Dana-Farber Cancer Institute, and Shreyaskumar R. Patel, MD, Center Medical Director of the Sarcoma Center ...

Continue reading

Chemoradiation Increases Secondary Sarcoma Risk in Patients With Abdominopelvic Cancers

The results of a new study found that patients receiving chemotherapy and radiation therapy simultaneously for abdominopelvic cancers were at higher risk of developing secondary sarcoma compared with patients who received surgery or radiation therapy alone for their treatment. "To our knowledge, this is the largest and most comprehensive series to estimate the risk of secondary sarcoma in a large group of adult patients treated for multiple primary abdominopelvic cancers...

Continue reading

Ripretinib for Advanced Gastrointestinal Stromal Tumor: Margaret von Mehren, MD

Ripretinib (QinlockTM, Diciphera Pharmaceuticals, LLC) represents a new option for patients with advanced gastrointestinal stromal tumor (GIST) previously treated with at least three kinase inhibitors, including imatinib. In this interview with i3 Health, Margaret von Mehren, MD, lead investigator of the INVICTUS study, on which ripretinib's recent FDA approval was based, discusses how this treatment compares with other options for advanced GIST in terms of efficacy and adverse events. What are ...

Continue reading

Kaposi Sarcoma: Pomalidomide Granted Accelerated Approval

In the first new drug approval for Kaposi sarcoma in over 20 years, the FDA has expanded the indication for pomalidomide (Pomalyst®, Celgene) in an accelerated approval, both for HIV-negative patients with Kaposi sarcoma and for patients with AIDS-related Kaposi sarcoma resistant to highly active antiretroviral therapy (HAART). The approval was based on data from Study 12-C-0047 (NCT01495598), an open-label, single-arm phase 1/2 trial in which 28 patients with Kaposi sarcoma, including 18 who we...

Continue reading